Promising Glaucoma Medication: A Comprehensive Translational Evaluation
Pharmaceutics · 02.07.2026 · 18 (7) · 822
DOI: 10.3390/pharmaceutics18070822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 02.07.2026. Verfasst von Doaa Nabih Maria und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NEI NIH HHS, Research to Prevent Blindness to the Hamilton Eye Institute.
Abstract (Originalsprache)
Background/Objectives: Despite available treatment options, glaucoma continues to be a leading cause of irreversible blindness. Current medications have multiple limitations, including rapid drainage, ocular irritation, requirement for multiple daily dosings, and systemic side effects. The current study was designed to engineer and characterize a pregabalin-containing enhanced delivery formulation (PRG-EDF) to directly address these inadequacies.
Methods
PRG-EDF eye drops were prepared using ingredients that are either U.S. Food and Drug Administration (FDA)-approved for ophthalmic use or have established safety profiles. The formulation was characterized using multiple evaluations, including pH, zetasizer analyses, viscosity, in vitro drug release, transcorneal permeability, determination of dose concentration and volume, systemic exposure, and potential for tachyphylaxis. Efficacy was evaluated using both Dutch belted rabbits and baboons.
Results
PRG-EDF provides extended release for up to 24 h. Ex vivo data reveal that PRG-EDF does not alter the inherent high PRG corneal permeability. An intraocular pressure (IOP) study using DB rabbits demonstrates that 40 µL of PRG-EDF, 0.6%, is the optimum dose of our formulation. Comparison of the efficacy of PRG-EDF with commercial products demonstrated its superiority in overall IOP-lowering efficacy. An extended in vivo assessment demonstrated that the potency of PRG-EDF reached maximum IOP-lowering amplitude after 4 weeks of daily dosing. Moreover, an in vivo bioadhesion assay demonstrated that EDF remained on the ocular surface for up to 24 h. Impressively, PRG-EDF is as effective in baboons as in rabbits.
Conclusions
We have successfully engineered a highly promising once-daily glaucoma medication with superior efficacy, as illustrated by higher IOP-lowering ability and prolonged duration of action.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
ORCID-Profile: Mohamed Moustafa Ibrahim, Sara N Maria, Monica M Jablonski
Förderung
- NIH HHS
- NEI NIH HHS
- Research to Prevent Blindness to the Hamilton Eye Institute
- University of Tennessee Research Foundation
- Hamilton Endowed Professorship
- UTHSC Neuroscience Institute
- UTHSC Collaborative Research Network
- Southwest National Primates Research Center
Zitieren
APA
Maria, D. N., Ibrahim, M. M., Maria, S. N., & Jablonski, M. M. (2026). Promising Glaucoma Medication: A Comprehensive Translational Evaluation. Pharmaceutics, 18(7), 822. https://doi.org/10.3390/pharmaceutics18070822
Vancouver
Maria DN, Ibrahim MM, Maria SN, Jablonski MM. Promising Glaucoma Medication: A Comprehensive Translational Evaluation. Pharmaceutics. 2026;18(7):822. doi:10.3390/pharmaceutics18070822
BibTeX
@article{Maria2026,
author = {Maria, Doaa Nabih and Ibrahim, Mohamed Moustafa and Maria, Sara N and Jablonski, Monica M},
title = {Promising Glaucoma Medication: A Comprehensive Translational Evaluation},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {7},
pages = {822},
doi = {10.3390/pharmaceutics18070822}
}
EUVIMED